Taro Pharma agrees to buyout offer from India's Sun Pharma

Mon Aug 13, 2012 9:12am IST

Related Topics

Stocks

   

Aug 12 (Reuters) - Taro Pharmaceutical Industries said late on Sunday it has agreed to be taken private by Sun Pharmaceutical Industries, weeks after it rejected an earlier $367 million bid from the Indian drugmaker.

All shareholders of Taro other than Sun Pharmaceutical and its affiliates will receive a cash payment of $39.50 per share upon the closing of the deal, according to the terms released.

Sun Pharmaceutical had earlier offered $24.50 per share, which was subsequently rejected by Taro.

Sun Pharmaceutical and its affiliates collectively own about 66 percent of the outstanding Taro ordinary shares and 100 percent of the shares of Taro's founders, representing about 77.5 percent of the outstanding voting power in Taro.

Based on 44.5 million shares outstanding, according to Reuters data, the one-third stake to be bought out by Sun Pharmaceutical is valued at $571.3 million.

The deal was approved by Taro's board of directors, the company said. Shares of Taro closed at $41.10 Friday on the New York Stock Exchange.

FILED UNDER:
  • Most Popular
  • Most Shared

Insight

REUTERS SHOWCASE

Border Talks

Border Talks

India names Ajit Doval as special envoy for China border talks.  Full Article 

WTO Deal

WTO Deal

U.S. seeks to step up India trade talks  Full Article 

Phone Masts

Phone Masts

American Tower to buy Bharti Nigeria phone masts for $1.1 billion  Full Article 

Infrastructure Plan

Infrastructure Plan

India targets private cash to build railways to its ports.  Full Article 

Shadow Banking

Shadow Banking

Reserve Bank planning more measures for NBFCs.  Full Article 

Auto Sector

Auto Sector

Hyundai Motor, Kia Motors lift 2014 global sales target on China, emerging markets  Full Article 

Oil Prices

Oil Prices

Some fund managers see oil falling to $60 without OPEC cut.  Full Article 

Project Shelved

Project Shelved

Jindal Steel shelves $10 bln project after coal setback.  Full Article 

Market Eye

Market Eye

Sensex, Nifty rise to record after China, ECB stimulus boosts risk appetite.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage